IQVIA Holdings Inc. (IQV)
NYSE · Healthcare · Diagnostics & Research
$266.09+3.05%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $43.8B
- P/E (trailing)
- 33.0
- Forward P/E
- 18.4
- 52-week range
- $154.50 – $277.40
- 52-week change
- +25.94%
- EPS (trailing)
- $8.05
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Oct 27, 2026
Fiscal year to Dec 2025
- Revenue
- $16.3B (+5.87%)
- Net income
- $1.4B
- Operating margin
- 13.4%
- Diluted EPS
- $7.84
- Free cash flow
- $2.1B
From the company’s annual report on SEC EDGAR.
About IQVIA Holdings Inc.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level.
Headquarters: Durham, United States · 94,000 employees · iqvia.com